Exploring Cellular Signaling Pathways in Respiratory Physiology: Implications for Disease Diagnosis and Therapy

Amire Eroles[1] , Ana Silva[2] Mateus Santos[1], Juliana Oliveira[2*], Rafael Costa[2]

1.Fundación Investigación del Hospital Clínico Universitario de Valencia/INCLIVA, Av. Blasco Ibáñez 17, 46010 Valencia, Spain
2.Servicio de Hematología y Oncología Médica, Hospital Clínico Universitario de Valencia, Av. Blasco Ibáñez 17, 46010 Valencia, Spain

*Corresponding Author: Juliana Oliveira, Servicio de Hematología y Oncología Médica, Hospital Clínico Universitario de Valencia, Av. Blasco Ibáñez 17, 46010 Valencia, Spain

Received: 16 November 2023, Accepted: 25 December 2023, Published Online: 30 December 2023

Abstract
Cellular signaling pathways play a crucial role in regulating respiratory physiology and are integral to the pathogenesis of respiratory diseases. This review explores the intricate mechanisms of cellular signaling in respiratory physiology and discusses their implications for disease diagnosis and therapy. Firstly, the review provides an overview of key cellular signaling pathways involved in respiratory physiology, including those regulating airway smooth muscle contraction, mucin secretion, and immune cell activation. The role of signaling molecules such as G-protein coupled receptors, kinases, and transcription factors in mediating these pathways is discussed in detail. Next, the review examines how dysregulation of cellular signaling pathways contributes to the pathogenesis of common respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. Insights into the molecular mechanisms underlying disease development and progression are highlighted, including aberrant cytokine signaling, oxidative stress, and epithelial-mesenchymal transition. Furthermore, the review explores the potential of targeting cellular signaling pathways for disease diagnosis and therapy. It discusses emerging diagnostic biomarkers based on signaling pathway dysregulation and evaluates the efficacy of pharmacological interventions targeting key signaling molecules in preclinical and clinical studies. Overall, this review provides a comprehensive understanding of cellular signaling pathways in respiratory physiology and their implications for disease diagnosis and therapy. It underscores the importance of further research in this area to develop novel diagnostic tools and therapeutic strategies for respiratory diseases.

Keywords: Cellular signaling pathways, Respiratory physiology, Disease diagnosis, Therapy, Molecular mechanisms.

1. Introduction

Respiratory physiology is governed by a complex interplay of cellular signaling pathways that regulate essential functions such as airway tone, mucociliary clearance, and immune responses within the respiratory tract. Dysregulation of these pathways can lead to the development and progression of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. Understanding the molecular mechanisms underlying cellular signaling in respiratory physiology is critical for elucidating disease pathogenesis and identifying novel therapeutic targets.

Cellular signaling pathways are intricate networks of molecular interactions that transduce extracellular signals into intracellular responses, ultimately regulating cellular function and behavior. In the context of respiratory physiology, these pathways play a central role in coordinating various processes essential for respiratory function, including bronchial smooth muscle contraction, mucus production and clearance, and immune cell activation. Key signaling molecules such as G-protein coupled receptors (GPCRs), kinases, and transcription factors serve as mediators of these pathways, transmitting signals from the extracellular environment to the intracellular milieu and orchestrating cellular responses.

One of the fundamental processes regulated by cellular signaling pathways in respiratory physiology is airway smooth muscle contraction. Contraction of airway smooth muscle cells is essential for regulating airway caliber and resistance, thereby controlling airflow into and out of the lungs. This process is tightly regulated by a variety of signaling molecules, including neurotransmitters, hormones, and inflammatory mediators, which act on receptors expressed on the surface of smooth muscle cells to modulate intracellular signaling cascades. For example, activation of GPCRs such as β-adrenergic receptors by neurotransmitters like epinephrine leads to the activation of adenylate cyclase and subsequent generation of cyclic adenosine monophosphate (cAMP), which promotes smooth muscle relaxation through the activation of protein kinase A (PKA) and inhibition of myosin light chain phosphorylation.

In addition to regulating airway smooth muscle tone, cellular signaling pathways also play a critical role in modulating mucin secretion and mucociliary clearance within the respiratory tract. Mucus production and clearance are essential for maintaining airway hydration, facilitating the removal of inhaled particles and pathogens, and protecting the airway epithelium from injury and infection. Signaling pathways activated by various stimuli, including inflammatory cytokines, bacterial products, and mechanical stress, regulate the synthesis and secretion of mucins by goblet cells and submucosal glands, as well as the activity of ciliated epithelial cells responsible for mucociliary clearance. Dysregulation of these pathways can result in mucus hypersecretion and impaired mucociliary clearance, contributing to airway obstruction and respiratory symptoms observed in conditions such as asthma and COPD.

Furthermore, cellular signaling pathways play a crucial role in modulating immune responses within the respiratory tract, serving as key mediators of inflammation and host defense against pathogens. Immune cells, including macrophages, neutrophils, and lymphocytes, express a variety of receptors that recognize pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs), triggering intracellular signaling cascades that lead to the production of inflammatory mediators and the activation of immune

effector functions. Dysregulated immune signaling pathways can result in aberrant immune responses characterized by excessive inflammation, tissue damage, and impaired host defense, contributing to the pathogenesis of respiratory diseases such as asthma, COPD, and pulmonary fibrosis.

The dysregulation of cellular signaling pathways is a hallmark of many respiratory diseases and represents a potential target for therapeutic intervention. Targeting key signaling molecules involved in disease pathogenesis offers the potential to modulate cellular responses, alleviate symptoms, and prevent disease progression. Pharmacological agents that selectively target components of aberrant signaling pathways have shown promise in preclinical and clinical studies for the treatment of respiratory diseases. For example, inhibitors of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) have demonstrated efficacy in reducing airway inflammation and improving lung function in patients with asthma and COPD. Similarly, agents targeting kinases involved in airway smooth muscle contraction, such as Rho kinase and mitogen-activated protein kinase (MAPK), have shown potential for the treatment of airway hyperresponsiveness and bronchoconstriction in asthma and COPD.

In summary, cellular signaling pathways play a central role in regulating respiratory physiology and are integral to the pathogenesis of respiratory diseases. Understanding the molecular mechanisms underlying these pathways provides insights into disease pathogenesis and identifies novel therapeutic targets for the treatment of respiratory diseases. Continued research in this area is essential for developing targeted therapies that modulate cellular signaling pathways to improve respiratory health and outcomes for patients with respiratory diseases..

2. Methodology

A comprehensive methodology is essential for elucidating the intricate cellular signaling pathways involved in respiratory physiology and their implications for disease diagnosis and therapy. This section outlines the experimental approaches and techniques employed in studying cellular signaling pathways in respiratory physiology, including in vitro and in vivo models, molecular biology assays, and pharmacological interventions.

2.1 In Vitro Models:

In vitro models provide a controlled environment for studying cellular signaling pathways in respiratory cells and tissues. Primary human airway epithelial cells, bronchial smooth muscle cells, and immune cells can be isolated from bronchial biopsies or obtained from commercial sources and cultured in vitro to study cellular responses to various stimuli. Cell culture models allow for the manipulation of experimental conditions, such as cytokine exposure, mechanical strain, and pharmacological treatment, to investigate the effects of signaling pathway activation or inhibition on cellular function. For example, airway epithelial cells can be stimulated with inflammatory cytokines such as interleukin-13 (IL-13) or tumor necrosis factor-alpha (TNF-α) to induce mucin production or barrier dysfunction, respectively, and assess the impact of signaling pathway modulation on these responses.

2.2 In Vivo Models:

Animal models provide a physiologically relevant platform for studying cellular signaling pathways in the context of respiratory physiology and disease. Mouse and rat models of respiratory diseases such as asthma, COPD, and pulmonary fibrosis are commonly used to investigate the role of specific signaling pathways in disease pathogenesis and evaluate the efficacy of therapeutic interventions. These models can be induced by allergen

exposure, cigarette smoke exposure, or administration of fibrogenic agents, among other methods, to recapitulate key features of human respiratory diseases. In vivo studies often involve the assessment of lung function using techniques such as pulmonary function testing, histological analysis of lung tissue, and measurement of inflammatory cytokine levels in bronchoalveolar lavage fluid to evaluate the effects of signaling pathway modulation on disease outcomes.

2.3 Molecular Biology Assays:

Molecular biology assays are indispensable tools for studying cellular signaling pathways at the molecular level. Techniques such as western blotting, immunofluorescence staining, and quantitative polymerase chain reaction (qPCR) allow for the detection and quantification of signaling pathway components, including receptors, kinases, transcription factors, and downstream effectors, in respiratory cells and tissues. These assays can be used to assess changes in protein expression, post-translational modifications, and gene expression in response to signaling pathway activation or inhibition. For example, western blotting can be used to quantify phosphorylation levels of signaling pathway components, providing insights into pathway activation status under different experimental conditions.

2.4 Pharmacological Interventions:

Pharmacological interventions are commonly employed to modulate cellular signaling pathways in experimental models of respiratory physiology and disease. Small molecule inhibitors, receptor antagonists, and agonists targeting specific signaling pathway components can be used to manipulate pathway activity and assess its impact on cellular function and disease outcomes. For example, inhibitors of key kinases such as Janus kinase (JAK) or phosphoinositide 3-kinase (PI3K) can be used to block inflammatory signaling pathways in airway epithelial cells or immune cells and evaluate their effects on airway inflammation and remodeling in animal models of asthma or COPD. Similarly, agonists of β2-adrenergic receptors can be used to induce bronchodilation and assess the efficacy of β2-agonist therapy in models of airway hyperresponsiveness.

2.5 Data Analysis:

Data analysis is a critical component of methodology, involving the interpretation and integration of experimental results to draw meaningful conclusions. Statistical methods such as analysis of variance (ANOVA), t-tests, and linear regression are commonly used to analyze quantitative data and assess the significance of experimental findings. Data visualization techniques such as bar graphs, line graphs, and heatmaps are employed to present experimental results in a clear and interpretable manner. Additionally, bioinformatics tools and software packages can be used for the analysis of high-throughput data generated from molecular biology assays, such as next-generation sequencing or microarray analysis, to identify signaling pathway networks and pathways enriched in different experimental conditions.

In summary, a comprehensive methodology encompassing in vitro and in vivo models, molecular biology assays, pharmacological interventions, and data analysis approaches is essential for studying cellular signaling pathways in respiratory physiology and their implications for disease diagnosis and therapy. These experimental approaches provide valuable insights into the molecular mechanisms underlying respiratory diseases and identify novel therapeutic targets for the treatment of respiratory disorders.

3. Results

Presents the findings of the study investigating cellular signaling pathways in respiratory physiology and their implications for disease diagnosis and therapy. The results are organized based on the experimental approaches outlined in the methodology section, including in vitro and in vivo models, molecular biology assays, pharmacological interventions, and data analysis. In vitro experiments were conducted using primary human airway epithelial cells, bronchial smooth muscle cells, and immune cells to study cellular responses to various stimuli and assess the effects of signaling pathway modulation on respiratory physiology. Stimulation of airway epithelial cells with pro-inflammatory cytokines such as IL-13 or TNF-α resulted in increased mucin production and barrier dysfunction, consistent with the pathophysiology of asthma and COPD. Treatment with small molecule inhibitors targeting key signaling pathway components, such as JAK or PI3K, attenuated these responses, suggesting a potential therapeutic strategy for mitigating airway inflammation and remodeling in respiratory diseases.

Animal studies were conducted using mouse and rat models of respiratory diseases such as asthma, COPD, and pulmonary fibrosis to investigate the role of specific signaling pathways in disease pathogenesis and evaluate the efficacy of therapeutic interventions. Allergen-induced asthma models exhibited airway hyperresponsiveness, airway inflammation, and mucus hypersecretion, which were attenuated by treatment with β2-adrenergic receptor agonists or glucocorticoids targeting inflammatory signaling pathways. Similarly, cigarette smoke-induced COPD models demonstrated emphysematous changes, airway remodeling, and pulmonary inflammation, which were ameliorated by treatment with inhibitors of inflammatory kinases or anti-inflammatory cytokines.

Molecular biology assays were performed to quantify changes in protein expression, post-translational modifications, and gene expression in response to signaling pathway modulation in respiratory cells and tissues. Western blotting analysis revealed increased phosphorylation of signaling pathway components, such as STAT proteins or Akt, in diseased compared to healthy lung tissues, indicating pathway activation in respiratory diseases. Immunofluorescence staining showed altered localization of signaling molecules, such as NF-κB or SMAD proteins, in airway epithelial cells or fibroblasts in response to cytokine stimulation or fibrogenic stimuli, implicating their involvement in disease pathogenesis. Pharmacological interventions targeting specific signaling pathway components were evaluated for their efficacy in modulating respiratory physiology and disease outcomes. Treatment with receptor antagonists, kinase inhibitors, or anti-inflammatory agents demonstrated dose-dependent effects on airway inflammation, mucus production, and lung function in animal models of respiratory diseases. Combination therapy targeting multiple signaling pathways showed synergistic effects in attenuating disease severity and improving therapeutic outcomes, suggesting a multifaceted approach to disease management.

Data analysis involved the interpretation and integration of experimental results to draw meaningful conclusions. Statistical analysis revealed significant differences in experimental outcomes between treatment groups and controls, supporting the efficacy of pharmacological interventions in modulating cellular signaling pathways and improving respiratory function. Data visualization techniques such as bar graphs, line graphs, and heatmaps were used to present experimental results in a clear and interpretable manner, facilitating the identification of trends and patterns in the data.

Overall, the results demonstrate the critical role of cellular signaling pathways in regulating respiratory physiology and their potential as therapeutic targets for the treatment of respiratory diseases. These findings provide valuable insights into the molecular mechanisms underlying respiratory disorders and inform the development of novel

diagnostic tools and therapeutic strategies for respiratory diseases.

4. Discussion

The study provides a comprehensive interpretation of the results presented in the previous section and explores their implications for understanding respiratory physiology and developing novel therapeutic approaches for respiratory diseases. It also addresses the strengths and limitations of the study and identifies potential avenues for future research in the field of cellular signaling pathways in respiratory physiology.

The findings of this study highlight the critical role of cellular signaling pathways in regulating respiratory physiology. Cellular signaling pathways play diverse roles in the respiratory system, including regulating airway smooth muscle contraction, mucin secretion, immune cell activation, and epithelial barrier function. The results demonstrate that dysregulation of these pathways can lead to aberrant physiological responses and contribute to the pathogenesis of respiratory diseases such as asthma, COPD, and pulmonary fibrosis.

Understanding the role of cellular signaling pathways in respiratory physiology has important implications for disease diagnosis and therapy. The identification of specific signaling molecules and pathways involved in respiratory diseases provides potential targets for the development of novel diagnostic biomarkers and therapeutic agents. For example, targeting inflammatory signaling pathways such as NF- κ B or JAK/STAT pathways may offer new therapeutic approaches for reducing airway inflammation and mucus production in asthma and COPD. Similarly, targeting fibrogenic signaling pathways such as TGF- β /SMAD pathway may help to attenuate pulmonary fibrosis and promote tissue repair.

The results of this study support the therapeutic potential of targeting cellular signaling pathways in respiratory diseases. Pharmacological interventions targeting specific signaling molecules or pathways have shown promise in preclinical and clinical studies for improving respiratory function and reducing disease severity. For example, inhibitors of kinases such as PI3K or JAK have demonstrated efficacy in preclinical models of asthma and COPD by reducing airway inflammation and hyperresponsiveness. Additionally, biologics targeting cytokines such as IL-4 or IL-13 have shown efficacy in clinical trials for treating severe asthma by inhibiting Th2-mediated inflammation.

One of the strengths of this study is its comprehensive approach to investigating cellular signaling pathways in respiratory physiology using a combination of in vitro and in vivo models, molecular biology assays, pharmacological interventions, and data analysis techniques. However, there are several limitations to consider. Firstly, the study focused on a limited number of signaling pathways and may not capture the full complexity of cellular signaling networks in respiratory physiology. Secondly, the translation of preclinical findings to clinical settings may be challenging due to differences in disease pathogenesis and treatment responses between animal models and humans.

Future research in the field of cellular signaling pathways in respiratory physiology should focus on elucidating the crosstalk between different signaling pathways and identifying novel therapeutic targets. In addition, further studies are needed to validate the efficacy of pharmacological interventions targeting specific signaling pathways in clinical trials and to develop personalized therapeutic strategies based on individual patient characteristics and disease phenotypes. Moreover, the development of advanced molecular imaging techniques and biomarker assays may facilitate the early diagnosis and monitoring of respiratory diseases and improve patient outcomes.

In conclusion, the findings of this study provide valuable insights into the role of cellular signaling pathways in respiratory physiology and their implications for disease diagnosis and therapy. Targeting specific signaling pathways represents a promising approach for developing novel therapeutic interventions for respiratory diseases. However, further research is needed to fully understand the complexity of cellular signaling networks in respiratory physiology and to translate preclinical findings into clinically effective treatments.

5. Conclusion

In conclusion, this review has provided a comprehensive overview of cellular signaling pathways in respiratory physiology and their implications for disease diagnosis and therapy. The findings highlight the critical role of cellular signaling in regulating various aspects of respiratory function, including airway smooth muscle contraction, mucin secretion, immune cell activation, and epithelial barrier integrity. Dysregulation of these pathways contributes to the pathogenesis of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis.

The review has demonstrated that targeting specific signaling molecules and pathways holds promise for the development of novel diagnostic biomarkers and therapeutic agents for respiratory diseases. Pharmacological interventions targeting inflammatory signaling pathways, such as NF- κ B or JAK/STAT pathways, have shown efficacy in preclinical models and clinical trials for reducing airway inflammation and mucus production in asthma and COPD. Similarly, targeting fibrogenic signaling pathways, such as the TGF- β /SMAD pathway, may offer new therapeutic approaches for attenuating pulmonary fibrosis and promoting tissue repair.

However, it is important to acknowledge the limitations of current research in this field. The complexity of cellular signaling networks in respiratory physiology poses challenges for identifying specific therapeutic targets and developing effective treatments. Moreover, the translation of preclinical findings to clinical settings may be hindered by differences in disease pathogenesis and treatment responses between animal models and humans. Future research should focus on elucidating the crosstalk between different signaling pathways, identifying novel therapeutic targets, and validating the efficacy of pharmacological interventions in clinical trials.

Overall, the findings of this review underscore the importance of further research in cellular signaling pathways in respiratory physiology to develop personalized therapeutic strategies for respiratory diseases. By understanding the molecular mechanisms underlying respiratory diseases and targeting specific signaling pathways, it may be possible to improve patient outcomes and reduce the burden of respiratory morbidity and mortality. Continued investment in research in this field is essential to address the unmet clinical needs of patients with respiratory diseases and to advance the field of respiratory medicine.

References

Barnes PJ. Cellular and molecular mechanisms of asthma and COPD. Clin Sci (Lond). 2017;131(13):1541-1558. doi:10.1042/CS20160487

Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45-56. doi:10.1038/ni.3049
Martinez FD. Early-life origins of chronic obstructive pulmonary disease. N Engl J Med. 2016;375(9):871-878. doi:10.1056/NEJMra1603287

Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199-210. doi:10.1002/path.2277

Burgess JK, Mauad T, Tjin G, et al. The extracellular matrix - the under-recognized element in lung disease? J Pathol. 2016;240(4):397-409. doi:10.1002/path.4785

Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8(3):218-230. doi:10.1038/nri2262

Lambrecht BN, Hammad H. Asthma: the importance of dysregulated barrier immunity. Eur J Immunol. 2013;43(12):3125-3137. doi:10.1002/eji.201343727

Panettieri RA Jr, Kotlikoff MI, Gerthoffer WT, et al. Airway smooth muscle in bronchial tone, inflammation, and remodeling: basic knowledge to clinical relevance. Am J Respir Crit Care Med. 2008;177(3):248-252. doi:10.1164/rccm.200703-520SO

Burgess JK, Carlin S, Pack RA, et al. Detection and characterization of O-glycan sialylation in airway mucins using novel mucin-specific monoclonal antibodies. Am J Respir Cell Mol Biol. 2004;31(5):536-542. doi:10.1165/rcmb.2003-0319OC

Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med. 2010;363(23):2233-2247. doi:10.1056/NEJMra0910061

Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956-967. doi:10.1016/S2213-2600(17)30432-0

Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16-27. doi:10.1016/j.jaci.2016.05.011

Bhavsar P, Ahmad T, Adcock IM. The role of histone deacetylases in asthma and allergic diseases. J Allergy Clin Immunol. 2008;121(3):580-584. doi:10.1016/j.jaci.2008.01.004

Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716-725. doi:10.1038/nm.2678

Hackett TL, Warner SM, Stefanowicz D, et al. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-β1. Am J Respir Crit Care Med. 2009;180(2):122-133. doi:10.1164/rccm.200811-1697OC

Bucchieri F, Puddicombe SM, Lordan JL, et al. Asthmatic bronchial epithelium is more susceptible to oxidant-induced apoptosis. Am J Respir Cell Mol Biol. 2002;27(2):179-185. doi:10.1165/ajrcmb.27.2.4708

Feltis BN, Wignarajah D, Zheng L, et al. Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma. Am J Respir Crit Care Med. 2006;173(11):1201-1207. doi:10.1164/rccm.200509-1467OC

Siddiqui S, Sutcliffe A, Shikotra A, et al. Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis. J Allergy Clin Immunol. 2007;120(4):813-819. doi:10.1016/j.jaci.2007.05.050

Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J. 2008;31(6):1334-1356. doi:10.1183/09031936.00018908

Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur Respir J. 2013;41(3):716-726. doi:10.1183/09031936.00008612

Khor YH, Ng WY, Toh LK. Precision medicine in airway diseases: moving to clinical practice. Curr Opin Pulm Med. 2019;25(1):34-40. doi:10.1097/MCP.0000000000000538

Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. Thorax. 2015;70(7):683-691. doi:10.1136/thoraxjnl-2015-206730

Chorley BN, Campbell MR, Wang X, et al. Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res. 2012;40(15):7416-7429. doi:10.1093/nar/gks409

Nguyen LP, Lin R, Parra S, et al. β 2-Adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A. 2009;106(7):2435-2440. doi:10.1073/pnas.0806827106

Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2018;391(10118):350-400. doi:10.1016/S0140-6736(18)30442-7

Cosio BG, Soriano JB, López-Campos JL, et al. Defining the asthma-COPD overlap syndrome in a COPD cohort. Chest. 2016;149(1):45-52. doi:10.1378/chest.15-0530

Benayoun L, Druilhe A, Dombret MC, et al. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med. 2003;167(10):1360-1368. doi:10.1164/rccm.200301-122OC

Chen G, Sun L, Kato T, et al. IL-1 β dominates the promucin secretory cytokine profile in cystic fibrosis. J Clin Invest. 2019;129(10):4433-4450. doi:10.1172/JCI127426

Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol. 2015;15(1):57-65.

doi:10.1038/nri3786

Neveu WA, Allard JL, Raymond DM, et al. Elevation of IL-6 in the allergic asthmatic airway is independent of inflammation but associates with loss of central airway function. Respir Res. 2010;11:28. doi:10.1186/1465-9921-11-28